In 2023, Jacobio Pharmaceuticals Group completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources) and Scope 2 (indirect emissions from purchased energy).
However, Jacobio Pharmaceuticals Group has not published a category-level breakdown of its Scope 3 emissions, limiting visibility into specific value chain sources.
| Metric (tCO2e) | 2023 | 2022 | 2021 | 2020-2019 |
|---|---|---|---|---|
Total Scope 1 | 33.98a | 10a | 11.11a | |
Total Scope 2 | ||||
Unspecified Calculation Method | 1,476.44a | 884.98a | 819.33a | |
Total Scope 3 | N/A | N/A | N/A | |
Total Scope 1 Revenue Intensity (tCO2e/$M) | 3.8019a | 0.7272a | 0.4633a |
You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"
Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.
In 2023, the total operational greenhouse gas (GHG) emissions of Jacobio Pharmaceuticals Group amounted to 1,510.42 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).a
Compared to 2022, the total operational greenhouse gas (GHG) emissions of Jacobio Pharmaceuticals Group increased by 68.77%, suggesting that the company faced challenges in reducing its emissions from its core operations.a
In 2023, the total Scope 1 emissions of Jacobio Pharmaceuticals Group were 33.98 metric tons of CO₂ equivalent (tCO₂e).a
Since 2021, Jacobio Pharmaceuticals Group's Scope 1 emissions have increased by 205.85%, reflecting a rising long-term trend in Scope 1 emissions over time.a
Compared to the previous year (2022), Jacobio Pharmaceuticals Group's Scope 1 emissions increased by 239.8%, suggesting that the company faced challenges in reducing emissions from its directly owned or controlled operations.a
In 2023, Jacobio Pharmaceuticals Group reported Scope 2 greenhouse gas (GHG) emissions of 1,476.44 tCO₂e without specifying the calculation method.a
Since 2021, Jacobio Pharmaceuticals Group's Scope 2 greenhouse gas (GHG) emissions (Unspecified Calculation Method) have increased by 80.2%, reflecting a rising long-term trend in Scope 2 emissions over time.a
Compared to the previous year (2022), Jacobio Pharmaceuticals Group's Scope 2 emissions (Unspecified Calculation Method) rose by 66.83% in 2023, suggesting that the company faced challenges in reducing emissions from purchased electricity and energya
In 2023, Jacobio Pharmaceuticals Group reported its Scope 2 emissions using an unspecified methodology.a
In 2023, Jacobio Pharmaceuticals Group reported Scope 1 greenhouse gas (GHG) emissions of 33.98 tCO₂e and total revenues of USD 9 millions. This translates into an emissions intensity of 3.8 tCO₂e per millions USD.a
In 2023, Jacobio Pharmaceuticals Group reported a Scope 1 emissions intensity of 3.8 tCO₂e per millions USD. Compared to the peer group median of 13.51, this places the company below its industry benchmark, indicating it is more carbon-efficient than most competitors.a
In 2023, Jacobio Pharmaceuticals Group ranked 7 out of 23 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD).a
Jacobio Pharmaceuticals Group is therefore positioned in the mid-range of its industry, neither a clear leader nor a laggard in carbon efficiency.a